Novartis AG ADR annual ebitda for fiscal TTM was $22.4 billion, a decrease of 2.6% from $23.0 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| EBITDA (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | $22.4B | $23.0B | $20.7B | $18.3B | $14.7B | $30.9B | $17.2B | $15.6B | $20.2B | $14.6B | $14.6B | $14.3B | $17.7B | $15.9B | $16.4B | $17.1B | $15.8B | $12.8B | $12.5B | $10.6B | $10.2B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EBITDA (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| EBITDA | $5.4B | $5.1B | $5.8B | $6.1B | $5.8B | $5.2B | $5.6B | $5.2B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More NVS metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding
All NVS financial statements → Interactive NVS charts →
About TickerBase · Data methodology & sources